{
    "2020-11-25": [
        [
            {
                "time": "",
                "original_text": "智飞生物新冠疫苗乌国三期临床试验进入质检流程",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "新冠疫苗",
                        "乌国",
                        "三期临床",
                        "质检流程"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "抗击新冠疫情系列报告之五：新冠疫苗研发跟踪 需求与成本分析",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "研发跟踪",
                        "需求",
                        "成本分析"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【医药】阿斯利康新冠疫苗达到主要功效终点，医药进入配置阶段——医药行业周报——中性",
                "features": {
                    "keywords": [
                        "阿斯利康",
                        "新冠疫苗",
                        "主要功效",
                        "医药行业",
                        "配置阶段"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "31股获券商买入评级，泛亚微透目标涨幅达82.86%",
                "features": {
                    "keywords": [
                        "券商买入评级",
                        "泛亚微透",
                        "目标涨幅"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技",
                        "材料"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "市场结构性特征显著 关注三类低估值消费股",
                "features": {
                    "keywords": [
                        "市场结构",
                        "低估值",
                        "消费股"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "消费"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}